HIGHBuilt-in & outside partyPipeline
rese-cel
“10-K Item 1: 'Resecabtagene autoleucel, or rese-cel...our lead product candidate within the CARTA strategy.'”
CABA · Concentration risk · 10-K extracted
Cabaletta Bio (CABA) concentration risks
Updated
The most significant concentration Cabaletta Bio discloses is rese-cel, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Cabaletta Bio’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Cabaletta Bio's disclosed concentration risk centers entirely on pipeline dependency: resecabtagene autoleucel, or rese-cel, is described as the company's lead product candidate within its CARTA strategy. With only a single concentration claim disclosed, and no revenue, customer, or geographic split reported, the risk here is straightforwardly one of product-pipeline concentration — the company's near-term prospects hinge on the clinical and regulatory progress of this one candidate. This is better understood as a structural feature of a clinical-stage biotech than a counterparty-specific dependency in the sense of a customer or supplier relationship, though the filing's own framing treats it as carrying both clinical and strategic weight for the business. Because there is only one asset at this level of advancement disclosed, any setback — a trial failure, delay, or regulatory rejection — would likely have an outsized effect on the investment case, simply because there is no second program of comparable size disclosed to offset it. Investors should treat this concentration as the dominant single variable in the thesis until the pipeline broadens or rese-cel reaches a value-defining milestone.
For the engine’s reasoning on CABA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| CABA● | Cabaletta Bio, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.